Company announcements · 28/10/20261 min read
Adial Pharmaceuticals Announces Name Change to Azora Therapeutics and New Executive Team, Focused on Advancing AT177, an Oral, Colon-Targeted AhR Agonist for Ulcerative Colitis
Summary
Stockholders approved the conversion of the preferred stock issued in the June 2026 acquisition of Azora Therapeutics
Original source language: GlobeNewswire — Mergers and AcquisitionsOpen original release →